Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study

被引:0
作者
Kazuaki Enya
Ben T. Saji
Takuya Kato
Hiroyuki Okamoto
Emiko Koumura
机构
[1] Takeda Pharmaceutical Co. Ltd,Japan Development Center
[2] Toho University Omori Medical Center,First Department of Pediatrics
[3] Takeda Pharmaceutical Co. Ltd,Formerly Japan Development Center
来源
Advances in Therapy | 2018年 / 35卷
关键词
Angiotensin II receptor blocker; Azilsartan; Cardiology; Hypertension; Pediatric; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1181 / 1190
页数:9
相关论文
共 59 条
  • [1] Shimamoto K(2014)The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014) Hypertens Res 37 253-390
  • [2] Ando K(2004)Overweight, ethnicity, and the prevalence of hypertension in school-aged children Pediatrics 113 475-482
  • [3] Fujita T(2010)Hypertension in children and adolescents: epidemiology and natural history Pediatr Nephrol 25 1219-1224
  • [4] Sorof JM(2012)Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study Hypertens Res 35 552-558
  • [5] Lai D(2017)Azilsartan in patients with mild to moderate hypertension using clinic and ambulatory blood pressure measurements J Clin Hypertens 19 82-89
  • [6] Turner J(2008)Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years J Clin Hypertens (Greenwich) 10 743-750
  • [7] Poffenbarger T(2011)Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension J Clin Hypertens (Greenwich) 13 357-365
  • [8] Portman RJ(2012)Azilsartan medoxomil: a review of its use in hypertension Clin Drug Investig 32 621-639
  • [9] Falkner B(2013)Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment Clin Pharmacokinet 52 347-358
  • [10] Rakugi H(2012)Single-center phase I study of the single- and multiple-dose pharmacokinetics and safety of azilsartan medoxomil (AZL-M) in hepatic impairment (abstract no. PII-99) Clin Pharmacol Ther 91 S89-1589